Search
RIO-North America study
Study characteristics:
1) 3045 obese patients, mean age 45 years, 80% women
2) mean BMI = 38
Treatment:
1) rimonabant 5 mg, 20 mg
2) placebo
Results:
1) 5 kg weight loss over 1 year (20 mg/day)
2) non-adherence 40%, dropout 7% [1]
General
clinical trial
References
- Pi-Sunyer FX et al, RIO-North America Study Group
Effect of rimonanbant, a cannabinoid-1 receptor blocker on
weight and cardiometabolic risk factors in overweight or obese
patients. RIO-Norht America: A randomized controlled trial.
JAMA 2006; 295:761
PMID: 16478899
- Simons-Morton DG et al,
Obesity research - Limitations of methods, measurements, and
medications.
JAMA 2006; 295:826
PMID: 16478906